
==== Front
World J Orthop
WJO
World Journal of Orthopedics
2218-5836
Baishideng Publishing Group Inc

jWJO.v15.i9.pg831
10.5312/wjo.v15.i9.831
94859
Editorial
Evolution of treatment options for juvenile idiopathic arthritis
Ren T et al. Treatment of juvenile idiopathic arthritis
Ren Tao Department of Colorectal Surgery, Taihe County People’s Hospital of Anhui Province, Fuyang 236600, Anhui Province, China

Guan Jia-Hui Department of Colorectal Surgery, Taihe County People’s Hospital of Anhui Province, Fuyang 236600, Anhui Province, China

Li Yu Department of Pharmacy, Taihe County People’s Hospital of Anhui Province, Fuyang 236600, Anhui Province, China

Li Nan-Nan University of Science and Technology of China, The First Affiliated Hospital of University of Science and Technology of China, Hefei 230001, Anhui Province, China

Li Zheng Jiangsu Engineering Research Center of Cardiovascular Drugs Targeting Endothelial Cells, College of Health Sciences, School of Life Sciences, Jiangsu Normal University, Xuzhou 221116, Jiangsu Province, China. lizhengcpu@163.com

Author contributions: Ren T acquisition, analysis and interpretation of data, drafting the article, final approval; Guan JH, Li Y, Li NN analysis and interpretation of data, final approval; Li Z conception and design of the study, critical revision, and final approval.

Corresponding author: Zheng Li, PhD, Pharmacist, Jiangsu Engineering Research Center of Cardiovascular Drugs Targeting Endothelial Cells, College of Health Sciences, School of Life Sciences, Jiangsu Normal University, No. 101 Shanghai Road, Xuzhou 221116, Jiangsu Province, China. lizhengcpu@163.com

18 9 2024
18 9 2024
15 9 831835
27 3 2024
27 7 2024
19 8 2024
©The Author(s) 2024. Published by Baishideng Publishing Group Inc. All rights reserved.
2024
https://creativecommons.org/licenses/by-nc/4.0/ This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial.
A recent study published in World J Clin Cases addressed the optimal non-steroidal anti-inflammatory drugs (NSAIDs) for juvenile idiopathic arthritis (JIA). Herein, we outline the progress in drug therapy of JIA. NSAIDs have traditionally been the primary treatment for all forms of JIA. NSAIDs are symptom-relief medications, and well tolerated by patients. Additionally, the availability of selective NSAIDs further lower the gastrointestinal adverse reactions compared with traditional NSAIDs. Glucocorticoid is another kind of symptom-relief medications with potent anti-inflammatory effect. However, the frequent adverse events limit the clinical use. Both NSAIDs and glucocorticoid fail to ease or prevent joint damage, and the breakthrough comes along with the disease-modifying antirheumatic drugs (DMARDs). DMARDs can prevent disease progression and reduce joint destruction. Particularly, the emergence of biologic DMARDs (bDMARDs) has truly revolutionized the therapeutics of JIA, compared with conventional synthetic DMARDs. As a newly developed class of drugs, the places of most bDMARDs in the management of JIA remain to be well established. Nevertheless, the continuous evolution of bDMARDs raises hopes of improving long-term disease outcomes for JIA.

Juvenile idiopathic arthritis
Treatment
Non-steroidal anti-inflammatory drug
Disease-modifying antirheumatic drug
Evolution
==== Body
pmc Core Tip: In past decades, the pharmacological treatments for juvenile idiopathic arthritis (JIA) have undergone a dramatic evolution from non-steroidal anti-inflammatory drugs to disease-modifying antirheumatic drugs (DMARDs), especially the emergence of biologic DMARDs enable patients with refractory JIA to achieve disease remission. This editorial focuses on the progress in treatment options for JIA. We hope that this editorial could provide valuable information for use of anti-JIA drugs.

INTRODUCTION

Juvenile idiopathic arthritis (JIA) refers to a broad term characterizing all forms of arthritis occurred in children before 16 years of age. JIA is a common autoimmune disease and a leading cause of childhood disability[1]. As a heterogeneous group of arthritis, JIA may subside with age, or, often extend chronic disease and inflammation of the joints throughout middle age in a significant proportion of patients[2,3]. Clinical manifestations of JIA include joint pain, swelling and stiffness. Moreover, it usually accompanies other systemic symptoms of flaccid fever, rash, and enlargement of liver, spleen and lymph nodes[4,5].

The goal of treatment is to control disease activity and prevent complications. Current treatment options include non-pharmacological and pharmacological interventions. Non-pharmacological interventions, such as psychological rehabilitation and exercise, are indispensable and helpful to foster the normal psychosocial and social development of the child and to keep or restore joint function and normal mobility[6,7]. Pharmacological interventions are the mainstay in the management of JIA. The therapeutic strategies have evolved markedly, owing to the availability of a growing number of specific and potent medications. Herein, we specifically discuss the progress of pharmacological treatments for JIA.

NONSTEROIDAL ANTI-INFLAMMATORY DRUGS

Non-steroidal anti-inflammatory drugs (NSAIDs) have traditionally been the mainstay treatment for all forms of JIA. Although the era of biological targeted therapy comes, NSAIDs are still suggested as first-line therapy[8]. NSAIDs work by blocking cyclooxygenase (COX) synthesis to exert analgesic and anti-inflammatory effects[9]. They can alleviate joint pain, swelling, stiffness and fever, but have no effects on joint damage. NSAIDs are well tolerated by children with few side-effects. Moreover, the availability of COX-2 selective inhibitors further lowers the adverse reactions compared with traditional NSAIDs[10]. The most common traditional NSAIDs for JIA include naproxen and ibuprofen, while celecoxib and rofecoxib are frequently used selective NSAIDs[11]. However, the comparative effectiveness and safety between different NSAIDs remains inconclusive. Although two studies suggested the superiority of celecoxib in effectiveness and rofecoxib in safety over other NSAIDs[12,13], these findings still need to be confirmed by solid evidence. Noticeably, the duration of NSAID monotherapy for more than 2 months is discouraged if arthritis is still active[14].

GLUCOCORTICOID

Glucocorticoid is another kind of symptom-relief medication that can exert rapid and potent anti-inflammatory effect. Glucocorticoid is necessary when NSAIDs fail to provide desired efficacy. Intra-articular injection of glucocorticoid is the main treatment for monoarticular or oligoarticular JIA without systemic symptoms[15]. This topical therapy is very helpful for preventing deformities that occur after chronic arthritis. Triamcinolone hexacetonide is preferred for intra-articular injection, since it offers a more durable clinical response than the other available glucocorticoids[16]. Systemic glucocorticoid is usually restricted to systemic JIA with extra-articular manifestations[7]. Prednisone is often the drug of choice for oral administration. However, the adverse events (e.g., growth retardation, infection, and osteoporosis) limit the prolonged use of glucocorticoid at large dose[17].

DISEASE-MODIFYING ANTIRHEUMATIC DRUGS

Conventional synthetic disease-modifying antirheumatic drugs

Conventional synthetic disease-modifying antirheumatic drugs (csDMARDs) are usually used in the initial therapy of polyarthritis, and in the case of inadequate efficacy from first-line treatment for oligo-arthritis[16]. The introduction of methotrexate (MTX) was a significant milestone in csDMARDs[18]. MTX exerts long-acting anti-inflammatory effects mainly through inhibition of interleukin (IL)-1 production[19]. Owing to its sustained effectiveness and acceptable toxicity, MTX remains the first choice second-line drug for JIA that is not controlled by NSAIDs or intra-articular corticosteroid injection[20,21]. Noticeably, prolonging MTX administration for 12 months did not yield additional benefit after the achievement of disease remission by 6 months treatment[22]. The other commonly used csDMARDs include sulfasalazine, lefunomide and cyclophosphamide, and they produce anti-inflammatory effects through different mechanisms. Leflunomide is less effective than MTX[23], but it is still an effective treatment for patients with MTX intolerance[24]. In addition, sulfasalazine is often the csDMARD of choice in patients with enthesitis-related arthritis[25].

Biologic DMARDs

The pharmacological therapeutics for JIA are still evolving, in which biologic DMARDs (bDMARDs) represent the most active and revolutionary field. bDMARDs are mainly selective inhibitors targeting one of three major pro-inflammatory cytokines (TNF, IL-1β, and IL-6). The other newly developed agents include anti-T cell-specific inhibitors, CD20 monoclonal antibodies, and Janus kinase (JAK) inhibitors. They are usually given along with MTX to patients who have an inadequate response to MXT alone.

The first bDMARD introduced to the treatment of JIA is etanercept, a recombinant human TNF-α receptor antagonist. Subsequently, other anti-TNF drugs were developed, such as infliximab, adalimumab, golimumab and certolizumab. Etanercept has been demonstrated the sustained benefits in growth velocity, bone status, and quality of life, and achieving complete disease quiescence in half of the patients[26-28]. Adalimumab is found to be highly effective in patients with or without previous treatment by other biologic agents[29]. Moreover, adalimumab achieves higher response rate than infiximab which is not approved for use in JIA[30]. Golimumab fails to exert superior efficacy over placebo in a trial and it has not yet been approved for use in JIA[31]. Certolizumab is still being evaluated by an ongoing trial. Of these drugs, only etanercept and adalimumab are authorized for use in JIA by both the United States Food and Drug Administration (FDA) and the European Medicines Agency (EMA).

Other bDMARDs that have been approved to be effective in MTX-resistant JIA include IL-1 inhibitors and IL-6 inhibitors. Canakinumab, an IL-1 inhibitor, has been approved by FDA and EMA for use in systemic JIA[32], while Tocilizumab, a monoclonal antibody against IL-6 receptor, has been approved for use in both polyarticular and systemic JIA[33,34]. Unlike the key role of TNF-α in polyarticular JIA, increasing evidence suggests that the major pathogenic cytokines in active systemic JIA are IL-1 and IL-6[35,36]. Patients with the systemic subtype of JIA generally respond well to an IL-1 inhibitor or IL-6 inhibitor, whereas an anti-TNF agent could be less effective in this subtype.

Abatacept is a selective T-cell activation blocker by targeting cytotoxic T-lymphocyte-associated antigen-4. The efficacy and safety of abatacept in JIA have been evidenced by a double-blind randomized controlled withdrawal trial, and then it is approved in the United States and Europe for JIA[37]. Rituximab is a human mouse chimeric monoclonal antibody targeting B lymphocyte (CD20). It is recommended for children with JIA who remain highly or moderately active with poor prognostic factors after sequential treatment with anti-TNF drugs and abatacept[38]. Besides, some newer drugs have been developed for the treatment of JIA, mainly JAK inhibitors, e.g., tofacitinib[39], baricitinib[40] and ruxolitinib[41]. Their efficacy and safety have been established in randomized controlled trials, and some of them have already been approved for use in JIA.

CONCLUSION

Huge progress has been achieved in available medications and treatment recommendations. The pharmacological treatments have undergone a dramatic evolution from NSAIDs to DMARDs, especially bDMARDs. Although treatment of JIA remains difficult, new treatments offer valuable opportunities for some patients with refractory JIA.

Conflict-of-interest statement: All the authors report no relevant conflicts of interest for this article.

Provenance and peer review: Invited article; Externally peer reviewed.

Peer-review model: Single blind

Specialty type: Orthopedics

Country of origin: China

Peer-review report’s classification

Scientific Quality: Grade C

Novelty: Grade C

Creativity or Innovation: Grade D

Scientific Significance: Grade C

P-Reviewer: Salimi M S-Editor: Liu H L-Editor: A P-Editor: Zheng XM
==== Refs
1 Zaripova LN Midgley A Christmas SE Beresford MW Baildam EM Oldershaw RA Juvenile idiopathic arthritis: from aetiopathogenesis to therapeutic approaches Pediatr Rheumatol Online J 2021 19 135 34425842
2 d'Angelo DM Di Donato G Breda L Chiarelli F Growth and puberty in children with juvenile idiopathic arthritis Pediatr Rheumatol Online J 2021 19 28 33712046
3 Selvaag AM Aulie HA Lilleby V Flatø B Disease progression into adulthood and predictors of long-term active disease in juvenile idiopathic arthritis Ann Rheum Dis 2016 75 190 195 25362042
4 Mahmud SA Binstadt BA Autoantibodies in the Pathogenesis, Diagnosis, and Prognosis of Juvenile Idiopathic Arthritis Front Immunol 2018 9 3168 30693002
5 Kim JW Ahn MH Jung JY Suh CH Kim HA An Update on the Pathogenic Role of Neutrophils in Systemic Juvenile Idiopathic Arthritis and Adult-Onset Still's Disease Int J Mol Sci 2021 22
6 Häfner R Truckenbrodt H Spamer M Rehabilitation in children with juvenile chronic arthritis Baillieres Clin Rheumatol 1998 12 329 361 9890101
7 Wallace CA Current management of juvenile idiopathic arthritis Best Pract Res Clin Rheumatol 2006 20 279 300 16546057
8 Bansal N Pasricha C Kumari P Jangra S Kaur R Singh R A comprehensive overview of juvenile idiopathic arthritis: From pathophysiology to management Autoimmun Rev 2023 22 103337 37068698
9 Miller LG Prichard JG Current issues in NSAID therapy Prim Care 1990 17 589 601 2236338
10 Zhao WJ Deng JH Li CF Research progress in drug therapy of juvenile idiopathic arthritis World J Pediatr 2022 18 383 397 35364799
11 Giancane G Consolaro A Lanni S Davì S Schiappapietra B Ravelli A Juvenile Idiopathic Arthritis: Diagnosis and Treatment Rheumatol Ther 2016 3 187 207 27747582
12 Shi CL Zhang Y Zhang ZY Zhou J Tang XM Comparative Efficacy and Safety of Non-Steroidal Anti-Inflammatory Drugs in Patients With Juvenile Idiopathic Arthritis: A Systematic Review and Network Meta-analysis Indian Pediatr 2021 58 162 168 33632948
13 Zeng T Ye JZ Qin H Xu QQ Systematic review and network meta-analysis of different non-steroidal anti-inflammatory drugs for juvenile idiopathic arthritis World J Clin Cases 2024 12 2056 2064 38680254
14 Beukelman T Patkar NM Saag KG Tolleson-Rinehart S Cron RQ DeWitt EM Ilowite NT Kimura Y Laxer RM Lovell DJ Martini A Rabinovich CE Ruperto N 2011 American College of Rheumatology recommendations for the treatment of juvenile idiopathic arthritis: initiation and safety monitoring of therapeutic agents for the treatment of arthritis and systemic features Arthritis Care Res (Hoboken) 2011 63 465 482 21452260
15 Scott C Meiorin S Filocamo G Lanni S Valle M Martinoli C Martini A Ravelli A A reappraisal of intra-articular corticosteroid therapy in juvenile idiopathic arthritis Clin Exp Rheumatol 2010 28 774 781 20863449
16 Onel KB Horton DB Lovell DJ Shenoi S Cuello CA Angeles-Han ST Becker ML Cron RQ Feldman BM Ferguson PJ Gewanter H Guzman J Kimura Y Lee T Murphy K Nigrovic PA Ombrello MJ Rabinovich CE Tesher M Twilt M Klein-Gitelman M Barbar-Smiley F Cooper AM Edelheit B Gillispie-Taylor M Hays K Mannion ML Peterson R Flanagan E Saad N Sullivan N Szymanski AM Trachtman R Turgunbaev M Veiga K Turner AS Reston JT 2021 American College of Rheumatology Guideline for the Treatment of Juvenile Idiopathic Arthritis: Therapeutic Approaches for Oligoarthritis, Temporomandibular Joint Arthritis, and Systemic Juvenile Idiopathic Arthritis Arthritis Rheumatol 2022 74 553 569 35233993
17 Ravelli A Martini A Juvenile idiopathic arthritis Lancet 2007 369 767 778 17336654
18 Giannini EH Brewer EJ Kuzmina N Shaikov A Maximov A Vorontsov I Fink CW Newman AJ Cassidy JT Zemel LS Methotrexate in resistant juvenile rheumatoid arthritis. Results of the U.S.A.-U.S.S.R. double-blind, placebo-controlled trial. The Pediatric Rheumatology Collaborative Study Group and The Cooperative Children's Study Group N Engl J Med 1992 326 1043 1049 1549149
19 Solebo AL Rahi JS Dick AD Ramanan AV Ashworth J Edelsten C Members of the POIG Uveitis Delphi Group Areas of agreement in the management of childhood non-infectious chronic anterior uveitis in the UK Br J Ophthalmol 2020 104 11 16 31048286
20 Raab A Kallinich T Huscher D Foeldvari I Weller-Heinemann F Dressler F Kuemmerle-Deschner JB Klein A Horneff G Outcome of children with oligoarticular juvenile idiopathic arthritis compared to polyarthritis on methotrexate- data of the German BIKER registry Pediatr Rheumatol Online J 2021 19 41 33752685
21 Bakry R Klein MA Horneff G Oral or Parenteral Methotrexate for the Treatment of Polyarticular Juvenile Idiopathic Arthritis Eur J Rheumatol 2022 9 197 205 35943454
22 Foell D Wulffraat N Wedderburn LR Wittkowski H Frosch M Gerss J Stanevicha V Mihaylova D Ferriani V Tsakalidou FK Foeldvari I Cuttica R Gonzalez B Ravelli A Khubchandani R Oliveira S Armbrust W Garay S Vojinovic J Norambuena X Gamir ML García-Consuegra J Lepore L Susic G Corona F Dolezalova P Pistorio A Martini A Ruperto N Roth J Paediatric Rheumatology International Trials Organization (PRINTO) Methotrexate withdrawal at 6 vs 12 months in juvenile idiopathic arthritis in remission: a randomized clinical trial JAMA 2010 303 1266 1273 20371785
23 Silverman E Mouy R Spiegel L Jung LK Saurenmann RK Lahdenne P Horneff G Calvo I Szer IS Simpson K Stewart JA Strand V Leflunomide in Juvenile Rheumatoid Arthritis (JRA) Investigator Group Leflunomide or methotrexate for juvenile rheumatoid arthritis N Engl J Med 2005 352 1655 1666 15843668
24 Ayaz NA Karadağ ŞG Çakmak F Çakan M Tanatar A Sönmez HE Leflunomide treatment in juvenile idiopathic arthritis Rheumatol Int 2019 39 1615 1619 31327053
25 Ringold S Angeles-Han ST Beukelman T Lovell D Cuello CA Becker ML Colbert RA Feldman BM Ferguson PJ Gewanter H Guzman J Horonjeff J Nigrovic PA Ombrello MJ Passo MH Stoll ML Rabinovich CE Schneider R Halyabar O Hays K Shah AA Sullivan N Szymanski AM Turgunbaev M Turner A Reston J 2019 American College of Rheumatology/Arthritis Foundation Guideline for the Treatment of Juvenile Idiopathic Arthritis: Therapeutic Approaches for Non-Systemic Polyarthritis, Sacroiliitis, and Enthesitis Arthritis Rheumatol 2019 71 846 863 31021537
26 Giannini EH Ilowite NT Lovell DJ Wallace CA Rabinovich CE Reiff A Higgins G Gottlieb B Chon Y Zhang N Baumgartner SW Effects of long-term etanercept treatment on growth in children with selected categories of juvenile idiopathic arthritis Arthritis Rheum 2010 62 3259 3264 20669280
27 Billiau AD Loop M Le PQ Berthet F Philippet P Kasran A Wouters CH Etanercept improves linear growth and bone mass acquisition in MTX-resistant polyarticular-course juvenile idiopathic arthritis Rheumatology (Oxford) 2010 49 1550 1558 20444859
28 Solari N Palmisani E Consolaro A Pistorio A Viola S Buoncompagni A Gattorno M Picco P Ruperto N Malattia C Martini A Ravelli A Factors associated with achievement of inactive disease in children with juvenile idiopathic arthritis treated with etanercept J Rheumatol 2013 40 192 200 23204218
29 Schmeling H Minden K Foeldvari I Ganser G Hospach T Horneff G Efficacy and safety of adalimumab as the first and second biologic agent in juvenile idiopathic arthritis: the German Biologics JIA Registry Arthritis Rheumatol 2014 66 2580 2589 24942886
30 Cecchin V Zannin ME Ferrari D Pontikaki I Miserocchi E Paroli MP Bracaglia C Marafon DP Pastore S Parentin F Simonini G De Libero C Falcini F Petaccia A Filocamo G De Marco R La Torre F Guerriero S Martino S Comacchio F Muratore V Martini G Vittadello F Zulian F Longterm Safety and Efficacy of Adalimumab and Infliximab for Uveitis Associated with Juvenile Idiopathic Arthritis J Rheumatol 2018 45 1167 1172 29657140
31 Brunner HI Ruperto N Tzaribachev N Horneff G Chasnyk VG Panaviene V Abud-Mendoza C Reiff A Alexeeva E Rubio-Pérez N Keltsev V Kingsbury DJ Del Rocio Maldonado Velázquez M Nikishina I Silverman ED Joos R Smolewska E Bandeira M Minden K van Royen-Kerkhof A Emminger W Foeldvari I Lauwerys BR Sztajnbok F Gilmer KE Xu Z Leu JH Kim L Lamberth SL Loza MJ Lovell DJ Martini A Paediatric Rheumatology International Trials Organisation (PRINTO) and the Pediatric Rheumatology Collaborative Study Group (PRCSG) Subcutaneous golimumab for children with active polyarticular-course juvenile idiopathic arthritis: results of a multicentre, double-blind, randomised-withdrawal trial Ann Rheum Dis 2018 77 21 29 28507219
32 Ruperto N Brunner HI Quartier P Constantin T Wulffraat N Horneff G Brik R McCann L Kasapcopur O Rutkowska-Sak L Schneider R Berkun Y Calvo I Erguven M Goffin L Hofer M Kallinich T Oliveira SK Uziel Y Viola S Nistala K Wouters C Cimaz R Ferrandiz MA Flato B Gamir ML Kone-Paut I Grom A Magnusson B Ozen S Sztajnbok F Lheritier K Abrams K Kim D Martini A Lovell DJ PRINTO PRCSG Two randomized trials of canakinumab in systemic juvenile idiopathic arthritis N Engl J Med 2012 367 2396 2406 23252526
33 Brunner HI Ruperto N Zuber Z Keane C Harari O Kenwright A Lu P Cuttica R Keltsev V Xavier RM Calvo I Nikishina I Rubio-Pérez N Alexeeva E Chasnyk V Horneff G Opoka-Winiarska V Quartier P Silva CA Silverman E Spindler A Baildam E Gámir ML Martin A Rietschel C Siri D Smolewska E Lovell D Martini A De Benedetti F Paediatric Rheumatology International Trials Organisation PRINTO Pediatric Rheumatology Collaborative Study Group (PRCSG) Efficacy and safety of tocilizumab in patients with polyarticular-course juvenile idiopathic arthritis: results from a phase 3, randomised, double-blind withdrawal trial Ann Rheum Dis 2015 74 1110 1117 24834925
34 De Benedetti F Brunner HI Ruperto N Kenwright A Wright S Calvo I Cuttica R Ravelli A Schneider R Woo P Wouters C Xavier R Zemel L Baildam E Burgos-Vargas R Dolezalova P Garay SM Merino R Joos R Grom A Wulffraat N Zuber Z Zulian F Lovell D Martini A PRINTO PRCSG Randomized trial of tocilizumab in systemic juvenile idiopathic arthritis N Engl J Med 2012 367 2385 2395 23252525
35 De Benedetti F Martini A Is systemic juvenile rheumatoid arthritis an interleukin 6 mediated disease? J Rheumatol 1998 25 203 207 9489807
36 Pascual V Allantaz F Arce E Punaro M Banchereau J Role of interleukin-1 (IL-1) in the pathogenesis of systemic onset juvenile idiopathic arthritis and clinical response to IL-1 blockade J Exp Med 2005 201 1479 1486 15851489
37 Ruperto N Lovell DJ Quartier P Paz E Rubio-Pérez N Silva CA Abud-Mendoza C Burgos-Vargas R Gerloni V Melo-Gomes JA Saad-Magalhães C Sztajnbok F Goldenstein-Schainberg C Scheinberg M Penades IC Fischbach M Orozco J Hashkes PJ Hom C Jung L Lepore L Oliveira S Wallace CA Sigal LH Block AJ Covucci A Martini A Giannini EH Paediatric Rheumatology INternational Trials Organization Pediatric Rheumatology Collaborative Study Group Abatacept in children with juvenile idiopathic arthritis: a randomised, double-blind, placebo-controlled withdrawal trial Lancet 2008 372 383 391 18632147
38 Takakura M Shimizu M Mizuta M Inoue N Tasaki Y Ohta K Furuichi K Wada T Yachie A Successful treatment of rituximab- and steroid-resistant nephrotic syndrome with leukocytapheresis J Clin Apher 2018 33 409 411 29341230
39 Huang Z Lee PY Yao X Zheng S Li T Tofacitinib Treatment of Refractory Systemic Juvenile Idiopathic Arthritis Pediatrics 2019 143
40 Taylor PC Keystone EC van der Heijde D Weinblatt ME Del Carmen Morales L Reyes Gonzaga J Yakushin S Ishii T Emoto K Beattie S Arora V Gaich C Rooney T Schlichting D Macias WL de Bono S Tanaka Y Baricitinib versus Placebo or Adalimumab in Rheumatoid Arthritis N Engl J Med 2017 376 652 662 28199814
41 Bader-Meunier B Hadchouel A Berteloot L Polivka L Béziat V Casanova JL Lévy R Effectiveness and safety of ruxolitinib for the treatment of refractory systemic idiopathic juvenile arthritis like associated with interstitial lung disease: a case report Ann Rheum Dis 2022 81 e20 32054604
